The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1 year study results

被引：0
|
作者：
McClung, Michael R.
Benhamou, Claude-Laurent
Man, Zulema
Tlustochowicz, Witold
Zanchetta, Jose R.
Matzkin, Ellen
Olszynski, Wojciech P.
Recker, Robert
Delmas, Pierre D.
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR USA
[2] INSERM, Res Unit, U658, Orleans, France
[3] Ctr Med TIEMPO, Buenos Aires, DF, Argentina
[4] Cent Hosp, Mil Sch Med, Inst Internal Med, Dept Rheumatol, Warsaw, Poland
[5] Inst Invest, Buenos Aires, DF, Argentina
[6] Procter & Gamble Pharmaceut, Mason, MS USA
[7] Sanofi Aventis, Bridgewater, NJ USA
[8] Saskatoon Osteoporosis Ctr, Saskatoon, SK, Canada
[9] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
[10] INSERM, Res Unit 403, F-69008 Lyon, France
来源：
OSTEOPOROSIS INTERNATIONAL | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S217 / S218
页数：2
相关论文
共 23 条
  • [1] THE EFFICACY AND TOLERABILITY RISEDRONATE 75 MG DOSED ON 2 CONSECUTIVE DAYS A MONTH FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS-2-YEAR STUDY RESULTS
    Benhamou, C.
    McClung, M.
    Tlustochowicz, W.
    Man, Z.
    Zanchetta, J.
    Eusebio, R.
    Balske, A.
    Matzkin, E.
    Olszynski, W.
    Recker, R.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 21 - 21
  • [2] EFFICACY AND TOLERABILITY OF 75 MG RISEDRONATE DOSED ON TWO CONSECUTIVE DAYS A MONTH FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS OVER 2 YEARS
    McClung, Michael
    Balske, Ana
    Matzkin, Ellen
    Olszynski, W. P.
    Recker, Robert R.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S210 - S210
  • [3] Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
    Delmas, P. D.
    Benhamou, C. L.
    Man, Z.
    Tlustochowicz, W.
    Matzkin, E.
    Eusebio, R.
    Zanchetta, J.
    Olszynski, W. P.
    Recker, R. R.
    McClung, M. R.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (07) : 1039 - 1045
  • [4] Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
    P. D. Delmas
    C. L. Benhamou
    Z. Man
    W. Tlustochowicz
    E. Matzkin
    R. Eusebio
    J. Zanchetta
    W. P. Olszynski
    R. R. Recker
    M. R. McClung
    Osteoporosis International, 2008, 19 : 1039 - 1045
  • [5] The efficacy and tolerability of a once-a-month dosing regimen of 150 mg risedronate for the treatment of postmenopausal osteoporosis - the merit-OP study
    Delmas, P. D.
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. L.
    Man, Z.
    Eusebio, R.
    Beary, J. F.
    Burgio, D. E.
    Boonen, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S327 - S327
  • [6] A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
    Michael R. McClung
    Claude-Laurent Benhamou
    Zulema Man
    Witold Tlustochowicz
    Jose R. Zanchetta
    Rachelle Eusebio
    Ana M. Balske
    Ellen Matzkin
    Wojciech P. Olszynski
    Robert Recker
    Pierre D. Delmas
    Calcified Tissue International, 2013, 92 : 59 - 67
  • [7] A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
    McClung, Michael R.
    Benhamou, Claude-Laurent
    Man, Zulema
    Tlustochowicz, Witold
    Zanchetta, Jose R.
    Eusebio, Rachelle
    Balske, Ana M.
    Matzkin, Ellen
    Olszynski, Wojciech P.
    Recker, Robert
    Delmas, Pierre D.
    CALCIFIED TISSUE INTERNATIONAL, 2013, 92 (01) : 59 - 67
  • [8] Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study
    Racewicz, Artur J.
    Schofield, Pamela J.
    Cahall, David L.
    Cline, Gary A.
    Burgio, David E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3079 - 3089
  • [9] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. -L.
    Man, Z.
    Eusebio, R. A.
    Beary, J. F.
    Burgio, D. E.
    Matzkin, E.
    Boonen, S.
    Delmas, P.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299
  • [10] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M. R. McClung
    J. R. Zanchetta
    A. Racewicz
    C. Roux
    C.-L. Benhamou
    Z. Man
    R. A. Eusebio
    J. F. Beary
    D. E. Burgio
    E. Matzkin
    S. Boonen
    P. Delmas
    Osteoporosis International, 2013, 24 : 293 - 299
123